Biomarcadores en enfermedad inflamatoria intestinal: ¿sabe cómo utilizarlos?
Author
dc.contributor.author
Pérez de Arce Oñate, Edith
Author
dc.contributor.author
Sedano Muñoz, Rocío
Author
dc.contributor.author
Quera, Rodrigo
Admission date
dc.date.accessioned
2020-10-19T15:49:25Z
Available date
dc.date.available
2020-10-19T15:49:25Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Rev Med Chile 2020; 148: 362-370
es_ES
Identifier
dc.identifier.issn
0034-9887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177211
Abstract
dc.description.abstract
Biomarkers in inflammatory bowel disease are an essential tool in clinical practice. They allow a non-invasive evaluation of patients and thus guide decision-making at different stages of the disease, including diagnostic suspicion, severity assessment, relapse prediction, and treatment response. Although biomarkers in blood such as erythrocyte sedimentation rate and C-reactive protein, are the most commonly used biomarkers, because their low cost and accessibility, they lack specificity. Currently, fecal biomarkers offer greater reliability, applicability, and specificity. Fecal calprotectin is the most commonly used marker. This review discusses the advantages and disadvantages of biomarkers in inflammatory bowel disease, as well as their clinical applications and new biomarkers currently under research.